Animal health boosts Bayer's sales growth but 2016 forecast disappoints

On Feb. 25, Bayer announced that sales in its fourth quarter grew nearly 5% year over year to €11.3 billion ($12.3 billion) and that it pulled in total revenues for 2015 of €46.3 billion ($50.6 billion), up 12%. The company credited part of the rise to a star performer in its animal health business: the Seresto flea and tick collar. But sales of Bayer's Advantage line of flea and tick products fell 1.3%, the company said in a press release announcing earnings. And the company's 2016 forecast for animal health was muted, at best. Bayer expects revenues in the division to come in only slightly above the €1.5 billion ($1.6 billion) in sales it recorded in 2015, and it expects EBITDA to grow in the low to mid-single-digits over the 2015 pro forma result of €348 million ($380 million). Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…